Production (Stage)
CNS Pharmaceuticals, Inc.
CNSP
$0.811
$0.00370.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.61M | -14.86M | -17.06M | -15.97M | -17.46M |
| Total Depreciation and Amortization | 3.70K | 3.40K | 3.40K | 3.50K | 3.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.29M | 1.44M | 1.54M | 864.90K | 920.30K |
| Change in Net Operating Assets | -2.85M | -3.69M | 1.34M | 4.35M | 4.03M |
| Cash from Operations | -17.16M | -17.11M | -14.18M | -10.76M | -12.51M |
| Capital Expenditure | -4.20K | -4.20K | -2.20K | -3.90K | -3.90K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -4.20K | -4.20K | -2.20K | -3.90K | -3.90K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -300.10K | -300.90K | -340.40K | -372.80K | -405.60K |
| Issuance of Common Stock | 28.88M | 23.40M | 20.84M | 8.56M | 8.82M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 815.20K | -66.80K | -259.70K | -219.70K | -202.90K |
| Cash from Financing | 29.40M | 23.03M | 20.24M | 7.97M | 8.22M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 12.23M | 5.91M | 6.06M | -2.79M | -4.30M |